FDA Approves Novel Drug Enfortumab Vedotin for Urothelial Cancer
The US Food and Drug Administration has granted accelerated approval to the novel agent enfortumab vedotin (PADCEV, Astellas) for the treatment of locally advanced or metastatic urothelial cancer that has progressed on chemotherapy and immunotherapy.Source: Medscape
Marilu Henner Knew Failure Was 'Not an Option' After Husband's Bladder & Lung Cancer Diagnosis
In honor of lung cancer awareness month, Marilu Henner and her husband are sharing his inspiring battle. Henner, former star of the hit sitcom Taxi, and her husband Michael Brown appeared on Megyn Kelly Today on Tuesday, when they discussed his 2003 diagnosis with bladder cancer — followed by a lung cancer diagnosis two months later. “In the last five to 10 years, with immunotherapy, the ability to harness the body’s own immune system to tackle the cancer through clinical trials, we now have standard therapies that patients can get instead of chemotherapies in many cases — even in lung cancer,” said Dr. Roy Herbst, chief of medical oncology at the Yale Cancer Center. He also urged the importance of screening to detect cancer early on.Source: People Magazine
Yale doctor seeks to limit surgeries for small kidney tumors
Not all kidney cancers are killers, and many small tumors can be left alone or watched over time because there is a low risk they will become dangerous, according to Dr. Brian Shuch at the Yale School of Medicine. While doctors can detect more tumors because of increasingly sensitive tools, such as MRIs, surgery to remove the cancer is not called for in many cases, said Shuch, an assistant professor of urology and radiology. “Many of these small tumors are very indolent or wimpy — low grade or low aggressiveness and low potential to spread or cause harm,” Shuch said. As many as 90 percent of tumors smaller than 4 centimeters fall into this category. Some actually turn out to be benign, he said.Source: New Haven Regsiter
Multigene Test May Help Identify Hereditary Kidney Cancers
A multigene panel test could be a useful diagnostic tool to help clinicians identify patients with a hereditary kidney cancer syndrome, according to the results of a study published in Cancer. “We know that a large number of patients with kidney cancer have an inherited predisposition,” study researcher Brian Shuch, MD, of the department of urology at Yale School of Medicine in New Haven, Connecticut, told Cancer Therapy Advisor. “We are now able to test these patients with a multigene panel that can facilitate identification of a germline variant.”Source: Cancer Therapy Advisor
'Alternative Medicine' for Cancer Ups Death Risk
It's rare but it happens: a patient with a curable cancer rejects conventional medicine and initially chooses to receive only alternative treatments. Now researchers from the Yale Cancer Center in New Haven, Connecticut, find that this choice is associated with a 2.5-fold higher risk for death compared with conventional cancer treatment (CCT) The team had to comb through 10 years (2004-2013) of records in the National Cancer Database to find 280 early-stage cancer patients (with either breast, prostate, lung, or colorectal disease) whose treatment was coded as "other-unproven: cancer treatment administered by non-medical personnel." This alternative medicine-only group was then matched to 560 patients with the same types of cancer who received CCT, such as radiotherapy, chemotherapy, surgery, and hormone therapy.Source: Medscape
Local physician appointed to Commission on Cancer position
Preston Sprenkle , MD received a three-year appointment as Cancer Liaison Physician for the cancer program at VA Connecticut Healthcare System . Cancer Liaison Physicians are an integral part of cancer programs accredited by the American College of Surgeons Commission on Cancer (CoC).
Brian M. Shuch, MD became a 2016-2018 AUA/UCF Research Scholar
Brian M. Shuch, MD has become a 2016-2018 Research Scholar. The American Urological Society and the Urology Care Foundation created the Research Scholar Program to provide mentored research training awards to early-career investigators.
Progress in Immunotherapy Continues, But Pseudo-Expression Is a Concern
Interest is high among urologists and medical oncologists with “the explosion of checkpoint blockade inhibition studies” that initially made inroads in melanoma and non-small cell lung cancer (NSCLC), but is also gaining traction in bladder cancer, said Daniel Petrylak, MD, director of the Genitourinary Oncology Research Program and co-director of the Signal Transduction Program at the Yale Cancer Center during an OncLive Insights Expert Perspectives program about the management of muscle-invasiSource: OncLive
Groundbreaking Immunotherapy Against Bladder Cancer
The therapeutic weapons against various cancers have been multiplying rapidly, but for patients with urothelial bladder cancer (UBC), the options have barely improved in 30 years. Dr. Daniel Petrylak, MD and colleagues tested a new antibody on 15 patients whose metastatic urothelial bladder cancer had not been reduced by chemotherapy, typically the final option for such patients.Source: Breakthroughs
Dr. Brian Shuch received the YCCI Scholar Award
Dr. Shuch received the award as a CTSA Scholar. This award is intended to assist the doctor with career development as a clinical or translational scientist, and will provide protected time to conduct research, prepare data for publication, apply for grants, and begin to establish and independent research program.
Research in the News: Yale team devises ingenious method to attack cancer at its genetic source
MicroRNAs may be tiny — as few as 20 genetic letters, compared to 3 billion in the DNA of a human — but they play a major role in biology, helping to determine which genes are expressed or silenced. In the last 10 years, researchers at Yale and elsewhere have shown they play a major role in formation and spread of tumors.
EGFR Pioneer Keeps Focus on Individualizing Patient Care in Lab and Clinic
As director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven, Thomas J. Lynch Jr, MD, wears many hats. And, having built a career united around two abiding goals of clinical discovery and personalized patient care, that’s just the way he likes it.Source: OncLive